elamipretide Report issue

Biologics Peptide Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Elamipretide (also known as SS-31,, MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.   Wikipedia

Chemistry

  • SMILES: Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N
  • InChIKey: SFVLTCAESLKEHH-WKAQUBQDSA-N
  • Mol. Mass: 639.8
  • ALogP: -0.55
  • ChEMBL Molecule:
    elamipretide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

arg-dmt-lys-phe-nh2 | arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide | bendavia | d-arg-dmt-lys-phe-nh2 | elamipretide | mtp-131 | ss-31 peptide | ss31 peptide

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Antioxidants ()

Barth Syndrome (Phase 2/Phase 3)

Deficiency Diseases (Phase 3)

DNA, Mitochondrial (Phase 3)

Friedreich Ataxia (Phase 1/Phase 2)

Fuchs' Endothelial Dystrophy (Phase 1/Phase 2)

Geriatrics (Phase 2)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 2)

Hypertension, Renovascular (Phase 1/Phase 2)

Kidney Diseases (Phase 1)

Macular Degeneration (Phase 2)

Macular Edema (Phase 1/Phase 2)

Metabolism (Phase 3)

Mitochondrial Diseases (Phase 3)

Mitochondrial Myopathies (Phase 3)

Musculoskeletal Diseases (Phase 3)

Mutation (Phase 3)

Optic Atrophy, Hereditary, Leber (Phase 2)

Pathology (Phase 3)

Renal Artery Obstruction (Phase 1/Phase 2)

Reperfusion Injury (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue